on ABL DIAGNOSTICS (EPA:ABLD)
ABL Texcell Diagnostics: Latest Research Flash Note Released
On October 8, 2026, ABL Texcell Diagnostics announced the availability of the latest equity research report by All Invest Securities. The report, featuring a Buy recommendation and maintaining a target price of €8.7 per share, includes the impact of TEXCELL's activities on the company's growth. This information underscores the anticipated revenue expansion beyond 2026.
The research note, authored by analyst Jean-Pierre Loza, is now accessible via ABL Diagnostics' website. It remains essential reading for professional investors under Directive 2014/65/EU, given its detailed financial analysis.
ABL Texcell Diagnostics continues to innovate in molecular diagnostic solutions. The recent acquisition of TEXCELL's operations has broadened its focus, expanding into virology and biosafety testing. This strategic move aligns with the company's expertise in molecular biology and commitment to supporting the life sciences sector.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news